Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer
Forjaz, A.; Mojdeganlou, H.; Valentin, A.; Wetzel, M.; Lvovs, D.; Deshpande, A.; Shin, S. M.; Piya, S.; Rajapakshe, K. I.; Guerrero, P. A.; Pedro, B. A.; Sidiropoulos, D. N.; Wu, P.-H.; Bernard Pagan, V.; Demystifying Pancreatic Cancer Therapies TeamLab, ; Wirtz, D.; Fertig, E. J.; Kagohara, L. T.; Ho, W. J.; Kiemen, A. L.; Wood, L. D.
Show abstract
Resistance to systemic therapy is a major unmet challenge in pancreatic cancer. To identify potential mechanisms of resistance, we developed a novel 3D pipeline in clinical samples that uses deep learning to classify sensitive and persistent tumor cell populations based on morphological features, enabling subsequent molecular characterization of intratumoral heterogeneity. We applied this automated 3D pipeline to a cohort of human pancreatic cancer samples treated with neoadjuvant chemotherapy, identifying heterogeneity in response to therapy both between and within tumors. Application of spatial proteomics to these sensitive and persistent regions identified enhanced epithelial-to-mesenchymal transition and non-classical cell states in persistent cells, confirming our morphological classification. Integration of spatial transcriptomics in multiple pancreatic cancer cohorts associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy. Our validated 3D multi-omic pipeline is now poised for application to clinical trials, enabling discovery of resistance mechanisms and design of new therapeutic combinations to circumvent resistance. Statement of significanceWe developed a novel 3D multi-omic pipeline to identify mechanisms of resistance to chemotherapy in clinical samples. This approach associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy and is poised for broader application in neoadjuvant clinical trials.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.